文献速递乳腺癌

RAPCHEM研究10年随访:cT1-2N1乳腺癌按淋巴结反应定制放疗

Tailoring radiotherapy in cT1-2N1 breast cancer to nodal response on primary chemotherapy (RAPCHEM: BOOG 2010-03): 10-year follow-up results of a Dutch, prospective, registry study.
PubMed 文献 · Lancet Oncol · 2026-01-01

BACKGROUND: Indications for postoperative locoregional radiotherapy in cT1-2N1 breast cancer after primary systemic therapy are disputed.…

要点

  • 低、中、高危三组10年局部区域复发率无显著差异。
  • 部分省略放疗可减少放疗相关并发症并可能改善生活质量。

核心结论

  • cT1-2N1乳腺癌按原发化疗后淋巴结反应定制局部区域放疗,10年局部区域复发率低,无复发生存与总生存前景良好。

研究设计与样本

  • 荷兰17家放疗中心的前瞻性登记研究(RAPCHEM,BOOG 2010-03),纳入2011年1月1日至2015年1月1日cT1-2N1乳腺癌患者。
  • 共838例患者纳入10年随访分析:低危组291例、中危组370例、高危组177例。

关键数值与推荐

  • 低危组:保乳术后全乳放疗,乳房切除术后不放疗。
  • 中危组:全乳或胸壁放疗,不做区域淋巴结放疗。
  • 高危组:全乳或胸壁放疗加III-IV站区域淋巴结放疗。

临床怎么用

  • 对cT1-2N1(影像学可疑淋巴结≤3枚)接受原发化疗的患者,可依据淋巴结反应分层决定局部区域放疗范围。
  • 按淋巴结反应部分或完全省略放疗,有助于避免放疗相关并发症并可能改善生活质量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Indications for postoperative locoregional radiotherapy in cT1-2N1 breast cancer after primary systemic therapy are disputed. The previously published 5-year outcomes of the RAPCHEM study showed excellent locoregional control when radiotherapy was tailored to the nodal response after primary chemotherapy. Here, we present 10-year results. METHODS: In this prospective registry study (RAPCHEM, BOOG 2010-03), patients referred to one of 17 participating Dutch radiation oncology centres between Jan 1, 2011, and Jan 1, 2015, with cT1-2N1 breast cancer (with ≤3 suspicious nodes at imaging) treated with primary chemotherapy, followed by breast and axillary surgery, were included. Three risk groups, with corresponding radiotherapy guideline were defined: the low-risk group received whole breast radiotherapy after lumpectomy and no radiotherapy after mastectomy; the intermediate-risk group received whole breast or chest wall radiotherapy without regional nodal radiotherapy; and the high-risk group received whole breast or chest wall radiotherapy and regional nodal radiotherapy of levels III-IV. The current analysis presents the prespecified secondary endpoints of the study of 10-year isolated locoregional recurrence rate, 10-year recurrence-free interval, and 10-year overall survival. This trial is registered with ClinicalTrials.gov, NCT01279304. FINDINGS: 838 patients were included in the 10-year follow-up analysis: 291 in the low-risk group, 370 in the intermediate-risk group, and 177 in the high-risk group. The 10-year locoregional recurrence rate in all patients was 2·9% (95% CI 1·9-4·2), with locoregional recurrence rates of 2·4% (95% CI 1·1-4·7) in the low-risk group, 3·2% (1·8-5·4) in the intermediate-risk group, and 2·8% (1·1-6·1) in the high-risk group. No significant differences were seen in locoregional recurrence between the groups. The 10-year recurrence-free interval for all patients was 79·2% (76·2-81·8), and the 10-year overall survival for all patients was 83·0% (80·3-85·4). INTERPRETATION: Tailoring locoregional radiotherapy in cT1-2N1 breast cancer (with ≤3 nodes at imaging) to the nodal response after primary systemic therapy resulted in a low 10-year locoregional recurrence rate, with promising recurrence-free interval and overall survival. By (partially) omitting radiotherapy based on nodal response after primary systemic treatment, possible morbidity caused by the radiotherapy can be avoided, which could improve patients' quality of life. FUNDING: Dutch Cancer Society.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Mauritz AJW, de Munck L, Simons JM, et al. Tailoring radiotherapy in cT1-2N1 breast cancer to nodal response on primary chemotherapy (RAPCHEM: BOOG 2010-03): 10-year follow-up results of a Dutch, prospective, registry study. Lancet Oncol. 2026. PMID: 42372742. doi:10.1016/S1470-2045(26)00216-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。